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Cx30 exhibits unique characteristics including a long half-life when
assembled into gap junctions
John J. Kelly1, Qing Shao1, Daniel J. Jagger2 and Dale W. Laird1,3,*
ABSTRACT
In the present study we investigated the life cycle, trafficking,
assembly and cell surface dynamics of a poorly characterized
connexin family member, connexin 30 (Cx30; also known as
GJB6), which plays a critical role in skin health and hearing.
Unexpectedly, Cx30 localization at the cell surface and gap
junctional intercellular communication was not affected by
prolonged treatments with the endoplasmic reticulum (ER)–Golgi
transport inhibitor brefeldin A or the protein synthesis inhibitor
cycloheximide, whereas Cx43 (also known as GJA1) was rapidly
cleared. Fluorescent recovery after photobleaching revealed that
Cx30 plaques were rebuilt from the outer edges in keeping with older
channels residing in the inner core of the plaque. Expression of a
dominant-negative form of Sar1 GTPase led to the accumulation of
Cx30 within the ER, in contrast to a report that Cx30 traffics via a
Golgi-independent pathway. Co-expression of Cx30 with Cx43
revealed that these connexins segregate into distinct domains
within common gap junction plaques, suggesting that their
assembly is governed by different mechanisms. In summary, Cx30
was found to be an unusually stable, long-lived connexin (half-life
>12 h), which may underlie its specific role in the epidermis and
cochlea.
KEYWORDS:Connexin, Gap junction, Cx30, Connexin 30, Life cycle,
Trafficking
INTRODUCTION
Gap junctions are intercellular channels that permit the direct
transfer of ions and small molecules (<1–1.5 kDa in size) between
adjacent cells, in a process termed gap junctional intercellular
communication (GJIC) (Alexander and Goldberg, 2003). Each gap
junction channel, composed of two interdocked hexameric
connexons provided by apposing cells, can be composed of single
(homotypic) or mixed (heterotypic) connexin family members.
Under specific physiological conditions undocked connexons at the
cell surface can also function as hemichannels that exchange small
molecules between the intra- and extracellular environments (Evans
et al., 2006). Given that 21 connexin subtypes exist in humans and
that most cell types express more than one connexin at any one time,
a huge variety of gap junction and hemichannel configurations are
possible (Laird, 2006). This complexity is evident in the skin
epidermis, where up to ten different connexins are expressed at
various stages of the keratinocyte life cycle (Martin et al., 2014).
This suggests that each channel type will exhibit some unique
features and functions. Connexin 30 (Cx30; also known as GJB6) is
specifically expressed in skin keratinocytes (Di et al., 2001), brain
astrocytes (Dahl et al., 1996), retinal astrocytes (Mansour et al.,
2013) and various inner ear cell types (Forge et al., 2003a).
Mutations in the Cx30-encoding gene GJB6 cause skin disease or
hearing loss, or a combination of both (Xu and Nicholson, 2013),
suggesting an essential role for Cx30 in these systems.
The connexin life cycle is a dynamic process that leads to the
efficient and rapid turnover of gap junction plaques at the cell
surface, usually within 1.5–5 h (Laird et al., 1991; Laird et al., 1995;
Laing et al., 1997; Beardslee et al., 1998). Other than Cx46, which
has been shown to have a slow turnover rate in enucleated lens fibre
cells (Jiang et al., 1993), connexins are presumed to have similar
life cycles to that of Cx43 (also known as GJA1) (Laird,
2006). Generally, connexins are co-translationally inserted into
endoplasmic reticulum (ER) membranes before trafficking as
monomers or oligomers (Das et al., 2009) to the trans-Golgi
network where they complete their oligomerization into connexons
(Musil and Goodenough, 1993; Vanslyke et al., 2009). Vesicular
and tubular post-Golgi carriers transport connexons to the cell
surface in a process that, for Cx43 at least, requires intact
microtubules (Thomas et al., 2001; Thomas et al., 2005; Shaw
et al., 2007). Many interacting proteins bind to or phosphorylate
connexins, such as Cx43, to regulate localization, gap junction
clustering, channel functionality and turnover dynamics (Laird,
2010; Solan and Lampe, 2014). Many of these protein binding/
interacting sites are found within the C-terminal tail of Cx43, so the
question arises as to how smaller connexins with short C-terminal
tails, such as Cx26 (also known as GJB2) and Cx30, are regulated in
the absence of protein interacting sites. To date, very few studies
have investigated the life cycle of Cx30.
In contrast to Cx43, some reports have suggested variations in the
life cycle of Cx26, and more recently Cx30. Firstly, Cx26 has been
suggested to post-translationally insert into ER membranes in cell-
free in vitro systems (Ahmad et al., 1999; Zhang et al., 1996) and
even directly into plasma membranes (Ahmad and Evans, 2002).
However, these findings have not been confirmed in vivo. Secondly,
based on their insensitivity to the ER–Golgi transport blocker
brefeldin A (BFA), both Cx26 and Cx30 have been suggested to
traffic to the cell surface via Golgi-independent pathways (George
et al., 1999; Martin et al., 2001; Qu et al., 2009). In contrast, data
from our laboratory has shown that Cx26 follows a similar
trafficking pathway through the Golgi apparatus, similar to Cx43
(Thomas et al., 2005). Thirdly, the dependence on intact
microtubules for correct trafficking to the cell surface is essential
for Cx43 – which contains binding sites for both tubulin and ZO-1
(Giepmans et al., 2001a,b), but is not necessary for Cx26 targeting
in normal rat kidney (NRK) cells and rat mammary tumour BICR-
M1Rk cells (Thomas et al., 2001; Thomas et al., 2005) or Cx30 in
HeLa cells (Qu et al., 2009). In the latter study, Cx30 was shown toReceived 20 May 2015; Accepted 8 September 2015
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interact with actin and β-tubulin, but not the tight junction protein
ZO-1, suggesting a novel role for actin-based trafficking/
stabilization of Cx30 gap junctions (Qu et al., 2009).
In this study we have investigated various aspects of the Cx30 life
cycle, with particular focus on the trafficking and stability of Cx30
at the cell surface. In contrast to what has been reported for Cx26
previously (George et al., 1999; Martin et al., 2001) and has more
recently been suggested for Cx30 (Qu et al., 2009), we found that
Cx30 traffics via the classical secretory pathway through the Golgi
apparatus before reaching the cell surface. In comparison with the
short 1–5 h half-lives determined for Cx26, Cx32, Cx43 and Cx45
(Fallon and Goodenough, 1981; Traub et al., 1989; Laird et al.,
1991; Darrow et al., 1995; Laird et al., 1995; Laing et al., 1997;
Beardslee et al., 1998; Thomas et al., 2005), we found that Cx30 has
an unusually long half-life at the cell surface. In order to facilitate
differential clearing of Cx30 and Cx43 from the cell surface we
found that these connexins were segregated into distinct regions
within the same gap junction plaque. In addition, disrupting the
actin and microtubule cytoskeletal networks did not adversely affect
the stable nature of Cx30 plaques at the cell surface, whereas those
formed of Cx43 became less organized and internalized. These
features suggest that connexin turnover and life cycles vary
markedly between Cx30 and Cx43.
RESULTS
Cx30–GFP dynamics in living cells
To study Cx30 dynamics in living cells (without the influence
of other connexins) Cx30–green fluorescent protein (GFP) was
expressed in HeLa cells and its movement, remodelling and clearing
from the cell surface was assessed. HeLa cells were efficient in
assembling Cx30 gap junction plaques at the cell–cell interfaces
(Fig. 1). To assist in determining the dynamic properties of Cx30–
GFP gap junctions, we photobleached three clearly defined plaques
(Fig. 1, circles labelled 1, 2 and 3) and assessed their recovery over
time. Within the 2 h and 20 min recording period, the
photobleached plaques were relatively slow to recover and did not
fully reach pre-bleach levels; however, GFP fluorescence was
visible within the bleached areas (1 and 3), indicating partial plaque
replenishment. Note that the bleached plaque in region 2 did not
recover due to separation of the cells. Non-bleached plaques were
either very stable or were wholly internalised into a single cell in
structures similar in appearance to connexosomes, as has been
reported for other connexins (Jordan et al., 1999; Jordan et al., 2001;
Piehl et al., 2007). Interestingly, connexosomes were either
degraded rapidly and disappeared, or hovered near the cell surface
(see arrows, Fig. 1; Movie 1).
Cx30–GFP gap junction plaques are replenished at the outer
edge
To investigate Cx30 dynamics and gap junction plaque
replenishment further, Cx30–GFP plaques between HeLa cells
were photobleached (red box, Fig. 2) and fluorescence recovery after
photobleaching (FRAP) recorded over a 2 h period (Fig. 2).
Composite images of Cx30–GFP fluorescence (green) and DIC
were taken from a z-stack plane at the time points indicated in the
upper panel of Fig. 2. Z-stacks were also processed into three-
dimensional (3D) reconstructions for further in-depth FRAP analysis
and rotated so that the plaque region was almost en face (bottom
panels of Fig. 2 and Movie 2; only Cx30–GFP in green is shown).
After only 26 min a faint rim of Cx30–GFP fluorescence was visible
around the photobleached region (see arrows in bottom panel of
Fig. 2; Movie 2). The rim continued to increase in size and
fluorescence until completion of the recording. By the 2 h time point,
the gap junction plaque appeared somewhat similar in fluorescence
intensity to that of the prebleached plaque. The accrual of Cx30–GFP
in a ring-like structure around the photobleached region suggests that
plaque renewal occurs at the outer edge of established plaques.
Cx30 plaques persist at cell–cell interfaces in cultures
treated with the ER–Golgi trafficking inhibitor brefeldin A
Blocking protein transport from the ER to the Golgi apparatus with
BFA leads to an accumulation of Cx43 in the ER and, due to its fast
Fig. 1. Live cell time lapse imaging of
HeLa cells engineered to express Cx30–
GFP. Gap junction plaques were clearly
visible between cells at the 0 h time point
(arrows). Images were acquired every 20 s
and plaques labelled 1, 2 and 3 were
photobleached immediately after the 0 h
time point. There was partial fluorescent
recovery of the photobleached plaques as
evident in the ovals labelled 1 and 3. A gap
junction being internalized and degraded
after cell–cell separation is denoted by the
filled arrow whereas a connexosome that
remained close to the initial junction region
and was not degraded during the movie time
frame is denoted by a double arrow. Scale
bars, 10 µm.
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turnover rate, loss of Cx43 plaques at the cell surface within 6 h
(Laird et al., 1995; Martin et al., 2001; Thomas et al., 2005). We
investigated whether Cx30 exhibits similar kinetics in HeLa cells in
comparison with Cx26 and Cx43. Cx30 gap junction plaque
numbers were not noticeably reduced in the presence of BFA,
whereas Cx26 localization was more perinuclear and Cx43
exhibited a profile resembling the location of the ER (Fig. 3A).
Continuous introduction of neurobiotin into a single cell via whole-
cell patch clamp and subsequent streptavidin detection of
neurobiotin spread after 10 min revealed that BFA greatly reduced
coupling in Cx43- and Cx26-expressing cells (P<0.001) but not
Cx30-expressing cells (P=0.656, Fig. 3B). The resistance of Cx30
gap junctions to clearing from the cell surface in the presence of
BFA, even after prolonged treatments of 18 h, was further
confirmed in Cx30-expressing rat epidermal keratinocytes (REKs)
(Fig. 4A) and NRKs (Fig. 4B). In many REKs, Cx30 accumulated
in the ER, as determined by co-localization with the ER marker
protein disulphide isomerase (PDI; green, inset in Fig. 4A), but still
retained gap junction plaques (arrows, Fig. 4A). This indicates that
when ER-to-Golgi transport is blocked, Cx30 is unable to exit the
ER along the classical secretory pathway.
Cx30 trafficking to the cell surface is inhibited by a Sar1
dominant-negative mutant
Although Cx30 plaques were persistent at the cell surface in
the presence of BFA, we could not rule out the possibility of a
direct Golgi-independent trafficking pathway playing a role in
replenishing the gap junction plaques, as has been previously
suggested (Qu et al., 2009). To address this possibility we co-
expressed Cx43 or Cx30 together with a DsRed2-tagged dominant-
negative mutant (H79G) form of Sar1 (secretion-associated RAS-
related protein 1) to prevent protein transport to the cis-Golgi, as we
have reported previously (Thomas et al., 2005; Bhalla-Gehi et al.,
2010) (Fig. 5A,B). Wild-type Sar1 was localized to perinuclear
regions where its expression had no effect on Cx43 gap junction
plaque formation (Fig. 5A). Upon Sar1H79G expression Cx43
exhibited an ER-like pattern and appeared to lose gap junction
plaques at the cell surface (Fig. 5A). In a similar fashion, REKs
co-expressing Cx30 and wild-type Sar1 had no discrepancies in
their ability to form gap junction plaques, whereas Sar1H79G caused
Cx30 to be retained in an ER-like pattern and led to a loss of gap
junction plaques between cells (Fig. 5B). These results suggest that
Cx30 is transported through the Golgi apparatus.
Cx30 protein has an extended half-life compared with Cx43
in keratinocytes
To assess the relative half-life of Cx30, REKs that co-expressed
Cx30 and Cx43 were treated with the translational inhibitor
cycloheximide (CHX) for up to 8 h and connexin content was
evaluated by immunofluorescent labelling and western blots
(Fig. 6A,B). While Cx43 levels were quickly reduced (Fig. 6A,B),
Cx30 levels remained relatively unchanged for up to 8 h of CHX
treatment, suggesting that Cx30 has a prolonged half-life compared
with Cx43.
Fig. 2. Cx30 gap junctions are replenished at the plaque edge.Gap junction plaques within HeLa cells expressing Cx30–GFP were photobleached (red box)
and its fluorescence recovery recorded in 3D z-stacks every 20 s for 2 h. The top panel shows 2D, single-plane, DIC imageswith GFP fluorescence at various time
points after photobleaching. The white box indicates the 3D region shown in the lower panels (GFP only). The 6.2 µm stack is rotated so that the plaque is almost
en face (red box, panel 1). Plaque fluorescent replenishment began within 20 min after photobleaching and occurred progressively at the plaque boundary
(arrows) and returned to near prebleach fluorescent intensity within 2 h. 2D scale bar, 10 µm; 3D scale bars: x, 10 µm; y, 10 µm; z, 6 µm.
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To further assess the prolonged half-life for Cx30, REKs co-
expressing Cx43 and Cx30 were treated with BFA for 7 h before
separating the cell lysate into Triton-soluble (non-plaque pool) or
Triton-insoluble (plaque pool) fractions. In control cells,
immunoblot analysis revealed similar levels of total Cx43 in both
the soluble and insoluble fractions (Fig. 7A,B), whereas the
Fig. 3. Cx30 gap junction plaques are insensitive to BFA treatment in HeLa cells. (A) HeLa cells stably expressing Cx30, Cx26 or Cx43 were treated with
BFA for 7 h to disrupt ER-to-Golgi transport, as indicated by the dissociated Golgi apparatus (inset, green). Cx43 localization was mostly intracellular after
exposure to BFA, and was less pronounced for Cx26 and Cx30. Cx43 and Cx26 plaques were reduced at the cell surface, whereas Cx30 gap junction plaques
remained. (B) Gap junctional intercellular communication, as assessed by neurobiotin (red) spread, was significantly reduced in Cx43- and Cx26-expressing cell
lines after BFA treatment; however, there was no significant difference in the extent of transfer in Cx30-expressing cells. Scale bars, 10 µm (A); 50 µm (B).
P-values were calculated using Student’s t-test. ***P<0.001; ns, not significant.
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phosphorylated species (P1/P2) were more abundant in the insoluble
fraction (Fig. 7A,C) as expected, since these phosphorylation states
usually reflect mature gap junction plaques (Lampe and Lau, 2000).
Cx30 was more abundant in the insoluble fraction of control cells
(Fig. 7A,D). After BFA treatment, the soluble fractions were not
significantly different from the controls for both total Cx43
(Fig. 7B, P=0.236) and Cx30 (Fig. 7D, P=0.894), whereas levels
of Cx43 in the insoluble fractions decreased significantly (P<0.001,
Fig. 7B,C). Interestingly, insoluble Cx30 protein levels were not
significantly different after BFA treatment (Fig. 7D). The ratio of
insoluble protein after BFA treatment to control insoluble protein
revealed a significant reduction of the total (P<0.001) and
phosphorylated (P<0.001) Cx43 species in comparison with Cx30
(Fig. 7E). These results further suggest that Cx30 exhibits an
extended half-life projected to be >12 h (estimated from the average
reduction in intensity over 8 h, to the point where the intensity
would be predicted to have dropped by 50% from the starting value)
when assembled into gap junction plaques.
Disruption of cytoskeletal elements does not destabilize
Cx30 gap junctions
To determine the effect of disrupting cytoskeletal elements on
Cx30-containing gap junction plaques at the cell surface, REKs
expressing Cx30 and Cx43 were treated with cytochalasin B
(cytoB) to disrupt actin microfilaments (Fig. S1) or nocodazole
to depolymerize microtubules (Fig. S2). Treatment with cytoB
initiated a reduction in filamentous actin and led to a reduction in
cortical actin staining at the cell border; however, there was no
discernible change in Cx30 gap junction plaques even after 10 h
of treatment (Fig. S1). In contrast, Cx43 puncta at cell–cell
Fig. 4. Cx30 gap junction plaques
are insensitive to BFA treatment in
connexin-expressing cell lines.
(A) REKs expressing Cx43 (upper
panel, red) or Cx30 (lower panel, red)
were treated with BFA for up to 8 h. At
this point Cx30 plaques remained at
the cell surface (arrows) despite Cx30
accumulating in the ER, as indicated
by co-localization with the ER marker
PDI (green, inset), whereas Cx43 was
completely localized inside the cell.
(B) NRKs co-expressing Cx30 and
Cx43 were exposed to BFA for up to
18 h and double immunolabelled with
monoclonal mouse anti-Cx43 (red)
and polyclonal rabbit anti-Cx30
(green) antibodies. Even at 18 h strong
cell-surface, plaque-like staining of
Cx30 was evident (arrows), whereas
Cx43 was virtually absent from the
cell surface. Scale bars: 10 μm (A),
50 μm (B).
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interfaces (0 h) appeared reduced after 2 h of cytoB treatment
and Cx43 localization was more intracellular. This suggests
that actin filaments do not play a role in stabilizing Cx30 gap
junctions. Treatment with nocodazole completely depolymerized
microtubules within 2 h as assessed by β-tubulin staining (Fig. S2).
This had no detrimental effect on Cx30 gap junctions even after
10 h of treatment while many cell surface Cx43 plaques were lost
after only 2 h of treatment.
Cx30 and Cx43 segregate and partition into distinct regional
domains within the same gap junction plaques
Since Cx30 and Cx43 can be temporally co-expressed within
keratinocytes in vivo we wanted to assess whether they fully
intermixed within a gap junction plaque, or whether they partitioned
into separate regions of the same plaque. REKs expressing Cx30–
GFP and immunolabelled for Cx43 revealed that these connexins
were localized to the same plaques (Fig. 8A); however, most of the
Cx43 puncta were distinct from Cx30–GFP plaque regions
(Fig. 8B–D). Next we used immunolabelling to examine the
localization pattern of Cx30 and Cx43 in NRKs (Fig. 8E). High
resolution z-stacks that were deconvolved into 3D images and
rotated on a side angle revealed that Cx30 and Cx43 segregated into
distinct, non-overlapping domains (Fig. 8F,G). In comparison,
cells expressing both Cx30–GFP and Cx26–red fluorescent protein
(RFP) had over-lapping expression patterns (Fig. 8H–K), which
is indicative of heteromeric or heterotypic gap junction
configurations, as described previously (Marziano et al., 2003).
DISCUSSION
Cx30 is a critical connexin in hearing and skin homeostasis. We and
others have shown that loss-of-function Cx30 gene mutations can
lead to severe deafness and devastating skin diseases or both (Grifa
et al., 1999; Essenfelder et al., 2004; Schutz et al., 2010;Wang et al.,
2011; Berger et al., 2014; Bosen et al., 2014). Yet the cellular life
Fig. 5. Expression of a dominant-negative
Sar1 mutant inhibits Cx30 trafficking to
the cell surface. REKs expressing Cx43 or
Cx30 together with Sar1-DsRed2 (WT) or
Sar1H79G-DsRed2 (MUT) were
immunolabelled for Cx43 (A) or Cx30 (B).
Sar1-DsRed did not disrupt trafficking of Cx43
or Cx30 to the cell surface, whereas Sar1H79G-
DsRed2 led to retention of both connexins in
the ER. Scale bars, 10 µm.
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cycle of this connexin remains poorly studied. Insights into its
normal life cycle may help determine how it serves essential roles in
both hearing and epidermal function. In this study we provide
compelling evidence in multiple cell types, including keratinocytes,
that Cx30 exhibits a prolonged life in gap junctions (half-life >12 h)
where it acts to maintain a stable level of GJIC. Thus Cx30 is a novel
connexin deviating from the short half-life of most other connexins
(half-lives of 1–5 h) that are expressed in cells that actively progress
through the cell cycle (Fallon and Goodenough, 1981; Traub et al.,
1989; Laird et al., 1991; Darrow et al., 1995; Laird et al., 1995;
Laing et al., 1997; Beardslee et al., 1998; Thomas et al., 2005). Our
studies suggest that Cx30 may acquire a prolonged half-life
compared with Cx43 by segregating into distinct subdomains
within gap junction plaques although it can fully intermix with the
highly homologous Cx26. Like many, if not all connexins studied to
date, Cx30 follows the classical secretory pathway by trafficking in
a COPII-dependent manner through the Golgi apparatus. Distinct
from Cx43, we also show that the stability of Cx30 gap junction
plaques are not affected by cytoskeletal-disrupting drugs, whereas
other aspects of the life cycle, such as gap junction renewal
and internalization via connexosomes, appear similar to other
connexins.
Cx30 dynamics were assessed using time-lapse imaging of live
cells expressing Cx30–GFP in connexin-deficient HeLa cells. We
have previously shown that the presence of GFP does not affect
the ability for Cx30 to traffic to the cell surface and form
functional gap junction channels and hemichannels (Berger et al.,
2014). While a few Cx30 plaques were dynamic, splitting up and
Fig. 6. Cx30 is a long-lived connexin. REKs
expressing Cx43 and engineered to express
Cx30 were exposed to 10 µg/ml cycloheximide
(CHX) for up to 8 h. Immunofluorescent labelling
(A) and western blotting of total protein lysates
(B) revealed a steady decline in Cx43
expression, whereas Cx30 localization and
expression levels remained relatively constant
during up to 8 h of CHX treatment. Scale bars,
10 µm. ***P<0.001.
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rejoining again on numerous occasions, most plaques were
immobile and stable at the cell surface. This could, however, be
due to the presence of an enhanced GFP (EGFP) tag at the
C-terminus that may reduce Cx30 fluidity in the plasma membrane
(Stout et al., 2015). In some instances, such as when cells were
migrating or dividing, whole Cx30–GFP plaques were internalized
into connexosome-like structures, as has been reported for gap
junction endocytosis previously (Jordan et al., 2001; Gaietta et al.,
2002; Piehl et al., 2007; Leithe et al., 2012). Interestingly,
connexosomes appeared to separate into two groups: some that
were rapidly internalized and likely to be degraded, and others that
remained in close proximity to the cell–cell border throughout the
duration of the movie (∼2 h). FRAP experiments revealed that,
similar to Cx43 gap junctions (Gaietta et al., 2002; Lauf et al.,
2002; Falk et al., 2009), Cx30 gap junction plaques were
replenished from the outer edge as older channels remained
sequestered to the inner aspects of the plaques. Together, live cell
examination of Cx30 gap junctions revealed that they are slow to
turnover but when they do, they appear to follow the well-studied
connexosome internalization pathway denoted by Cx43 (Jordan
et al., 2001; Gaietta et al., 2002; Piehl et al., 2007; Leithe et al.,
2012). Furthermore, Cx30 gap junction plaque replenishment at
the cell surface appears to be identical to Cx43 gap junctions
(Gaietta et al., 2002; Lauf et al., 2002) in that new channels are
sequestered to the outer edges of the plaques while older channels
form the core of the plaque.
A report by Qu and colleagues (Qu et al., 2009) suggested that
Cx30 could traffic to the cell surface via a Golgi-independent
pathway in HeLa cells. This was also previously suggested for
Cx26 in HeLa and COS-7 cells (Martin et al., 2001); however, we
found that this was not the case for Cx26 in rat mammary tumour
(BICR-M1Rk) or NRK cell lines (Thomas et al., 2005). In the
present study, we concluded that Cx30 was routed through the
classical secretory pathway in multiple cell types including
keratinocytes based on: (1) its accumulation in a merged
ER–Golgi compartment upon long-term treatment with BFA, (2)
co-localization with resident markers of the ER in long-term BFA-
treated cells and (3) accumulation in the ER compartment upon
Fig. 7. Cx30 remained in a Triton-
insoluble fraction after BFA treatment.
Control or BFA-treated REKs expressing
Cx30 and Cx43 were separated into Triton
X-100-soluble or -insoluble fractions and
analysed by western blot (green, A).
GAPDH (red) was used as a control
counterstain and was only detected in the
soluble fractions (A). The levels of total
Cx43 (B), phosphorylated Cx43 (C), total
Cx30 (D) and the ratio of BFA to control
insoluble fractions (E) were quantified from
three independent experiments. **P<0.01;
***P<0.001; ns, not significant. P0, P1 and
P2, phosphorylated species of Cx43.
3954
RESEARCH ARTICLE Journal of Cell Science (2015) 128, 3947-3960 doi:10.1242/jcs.174698
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
disruption of the Sar1-dependent protein transport pathway. Sar1 is
a small GTPase that recruits components of the coat protein
complex II (COPII) to the ER membrane in its active GTP-bound
form, whereas the mutant Sar1H79G used in this study is unable to
hydrolyse GTP to GDP and thus prevents Cx30 cargo-carrying
vesicles from being transported to the Golgi apparatus. These data
support a role for COPII-mediated transport of Cx30 vesicles along
the secretory pathway. Thus whether Cx30 is expressed in reference
cell types such as HeLa or NRK cells or expressed in
physiologically relevant keratinocytes, it is routed through the
Golgi apparatus to the cell surface. Trafficking of Cx30 to or from
the cell surface or the stability of pre-existing Cx30 gap junction
plaques appeared to be unaffected by disrupting the microfilament
or microtubule cytoskeletons. As previously demonstrated (Thomas
et al., 2005) and shown here, Cx43 trafficking and plaque status is
dramatically affected by the loss of microtubule integrity, whereas
Cx26 trafficking is not dependent on intact microtubule networks.
These data suggest that Cx43 assembly is more dependent on
microtubules than either Cx26 (Thomas et al., 2001; Thomas
et al., 2005) or Cx30. This may not be unexpected as the known
tubulin binding site in the C-terminal tail of Cx43 (Giepmans et al.,
2001a,b) is lacking in both Cx26 and Cx30.
Once assembled into a gap junction, we found that Cx30 has an
unexpectedly long half-life (>12 h) when directly compared with
Cx43, which has been well documented to have a short half-life of
1–5 h in vitro (Laird et al., 1991; Darrow et al., 1995; Laird et al.,
1995; Laing et al., 1997) and in vivo (Fallon and Goodenough,
1981; Beardslee et al., 1998). Several comparative experiments with
cells expressing or co-expressing both Cx43 and Cx30 suggested
that it was the fully assembled Cx30 gap junction plaques that were
long lived as opposed to a possible population of Cx30
hemichannels. Firstly, Cx30-expressing cells retained high levels
of GJIC even after prolonged BFA treatment. Secondly, Cx30 gap
junction localization was relatively unaffected by even long BFA
treatment times. Thirdly, Cx30 remained in a Triton X-100-
insoluble pool after BFA treatment. Finally, total Cx30 clearing
from the cell surface was highly delayed when cells were treated
with the protein synthesis inhibitor cycloheximide. These results
indicate that Cx30 has unique long-lived properties at the cell
surface. This property was previously thought to be restricted to lens
Fig. 8. Cx30 and Cx43 segregate into
distinct domains when co-expressed in
the same cell. (A) An en face view of a large
Cx30–GFPplaque (green) is shown between
overlapping REKs stained for Cx43 (red).
(B–D) Magnified image from boxed region
shows that Cx30–GFP and Cx43 were in
close proximity but remained distinct and did
not co-localize (arrows). (E–G) Untagged
Cx30 (green) and Cx43 (red) are also distinct
from each other in NRK cells. The image in F
is a 3D deconvoluted image made from E
with the boxed region shown in higher
magnification in G. Note the non-overlapping
localization of Cx30 and Cx43 at the cell
surface. (H–K) Cx30–GFP and Cx26-RFP
(red) co-localized in the same gap junction
plaque in REKs. An overhead projection is
shown in H and the boxed region magnified
and rotated in the subsequent panels (I–K).
The plaque (double arrow) in this instance
showed strong co-localization for Cx30–GFP
and Cx26–RFP. Scale bars, 10 µm (A), 5 µm
(B–D and H), 2 µm (G and I–K).
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gap junctions consisting of mammalian Cx46 (Jiang et al., 1993) or
chick Cx56 (Berthoud et al., 1999) in enucleated fibre cells, where
they maintain the metabolic homeostasis of the lens (Slavi et al.,
2014). This leads to the question: why would Cx30 need to have an
extended half-life at the cell surface when most other connexins are
designed to turn over rapidly?
Firstly, the long half-life of Cx30 gap junctions may partially
explain how Cx30 forms some of the largest-sized gap junction
plaques in the vertebrate body (Forge et al., 2003a). In the inner ear,
these large Cx30 gap junction plaques are found between
supporting cells within the avascular organ of Corti (Sun et al.,
2005; Jagger and Forge, 2006), which plays a key role in K+
buffering and metabolite transfer (Jagger and Forge, 2014).
Therefore, large gap junction plaques may be crucial for
maintaining homeostasis by maximizing cell–cell transfer of
metabolites and nutrients (Chang et al., 2008). In addition, long-
lived Cx30 gap junction plaques may play an important
physiological role in the skin. Cx30 is abundantly expressed in
the stratum granulosum, the most differentiated living keratinocyte
layer (Di et al., 2001; Churko and Laird, 2013). As keratinocytes
terminally differentiate in an avascular environment they lose their
intracellular components and establish a calcium gradient, which
becomes critical for epidermal health (Menon et al., 1985; Adams
et al., 2012). Interestingly, the lens is also an avascular organ (where
Cx46 and chick Cx56 have long half-lives) that requires stable gap
junctions to maintain the unique microcirculatory system of the lens
(Mathias et al., 2010). This suggests that long-lived, large gap
junction plaques may be essential for nutrient transfer through GJIC
as a compensatory mechanism for tissues that have no direct
vascularization.
Secondly, in vivo Cx30 expression in mammals appears to be
limited to quiescent cell types or cells undergoing terminal
differentiation. Evidence for this can be found in skin where Cx30
is expressed in terminally differentiated keratinocytes both in
human (Di et al., 2001; Richard, 2003; Churko and Laird, 2013)
and murine (Coutinho et al., 2003; Kretz et al., 2003) epidermis,
in non-proliferating astrocytes within the brain (Kunzelmann et al.,
1999) and retina (Mansour et al., 2013), in cochlear supporting
cells (Lowenheim et al., 1999; Chen et al., 2003) and mature
lateral wall fibrocytes that have become quiescent. In addition,
Cx30 is linked to differentiation of mammary gland cells during
lactation (Talhouk et al., 2005) and to calcium-induced
differentiation of corneal cells (Shurman et al., 2005). These
findings might suggest that long-lived Cx30 plaques are
preferentially expressed in quiescent cells or cells undergoing
terminal differentiation, perhaps to reduce the burden of constant
gap junction renewal and thus permit energy conservation, whilst
retaining gap junctional intercellular communication.
Thirdly, in addition to gap junctions mediating intercellular
communication, they have been proposed to play a role in cell–cell
adhesion (Elias et al., 2007; Falk et al., 2012), which might impact
upon processes such as wound healing. For example, in wounded
skin, up-regulation of Cx30 and Cx26 in all epidermal keratinocyte
layers, and a concomitant decrease in Cx43 at the wound edge, are
proposed to co-ordinate the keratinocyte wound healing response
(Coutinho et al., 2003; Churko and Laird, 2013). In the damaged
cochlea, Cx30 is also important for coordinating a wound healing
response after sensory hair cell death (Forge et al., 2013). In this
instance, supporting cells expand to fill the voids left by dead hair
cells and restore epithelial tight junction integrity. In Cx30−/−mice,
supporting cells not only display defects in repairing the space left
by dead hair cells, they also develop a highly unusual migratory
phenotype, despite still expressing Cx26, suggesting that Cx30
plaques may be important in controlling cell responses to injury
(Forge et al., 2013). The inability of terminally differentiated
keratinocytes and cochlear supporting cells to proliferate suggests
that long-lived Cx30 gap junctions may help to regulate GJIC or
cell–cell adhesion properties to collectively coordinate and control
wound healing responses.
Finally, our studies revealed that Cx30 was arranged into
distinct subdomains within plaques co-expressing Cx43, whereas
Cx30 and Cx26 fully intermixed. Similar findings have been
shown for Cx26 and Cx43 (Falk, 2000) and more recently with
Cx30 and Cx43 (Stout et al., 2015). However, Stout and
colleagues went on to suggest that Cx30 and Cx43 segregation
is attributed to using non-monomeric GFP tags at the C-terminus
of Cx30. When a monomeric variant of GFP was used, Cx30 and
Cx43 no longer segregated into distinct domains (Stout et al.,
2015), suggesting that the tag was governing the connexin
segregation. However, we found that untagged Cx43 and Cx30
segregate from each other in NRK cells expressing both
connexins, suggesting that, at least in some cells, they may
retain innate properties to segregate that are independent of issues
related to tagging. These findings are in agreement with previous
reports that α- (e.g. Cx43) and β-connexins (e.g. Cx26 and now
Cx30) fail to intermix within gap junction channels (Gemel et al.,
2004), whereas Cx26 and Cx30 have been shown to form
intermixed heteromeric gap junctions (Forge et al., 2003b; Yum
et al., 2007). How connexins intermix within channels and gap
junctions probably has importance when considering the nature of
connexin-linked diseases. For example, mutations in the Cx30
gene (GJB6) can cause palmoplantar hyperkeratosis, Clouston
Syndrome and/or hearing loss. Whether these clinical
presentations are associated with the disruption of the normal
Cx30 life cycle or function, or whether they are due to any gain-
of- or loss-of-function mutant effect on other co-expressed
connexins, remains poorly understood. Surprisingly, we have
previously shown that some Cx30 mutants acquire new properties
and can affect the localization of Cx43 (Berger et al., 2014), even
though here we show that wild-type Cx30 remains in distinct
subplaque domains from Cx43. One explanation for connexin
segregation could be due to the wealth of Cx43 binding partners
while the interactome for Cx30 is limited due to the small
C-terminal domain (Laird, 2010). As an example, ZO-1 binds to
the C-terminal tail of Cx43 (Giepmans et al., 2001b), but does not
bind to Cx30 (Qu et al., 2009), suggesting that ZO-1 could be a
candidate for preventing the intermixing of Cx30 and Cx43 in
keratinocytes.
In conclusion, this is the first study to demonstrate that Cx30
exhibits an unusually long half-life at the cell surface and that
disruption of either the actin or tubulin cytoskeletal networks does
not affect Cx30 gap junction stability. Interestingly, the main
tissue-specific cell types that express large amounts of Cx30,
namely the keratinocytes and inner ear supporting cells, are either
terminally differentiated or quiescent and are often found in
avascular tissue regions. These findings suggest that long-lived
Cx30 gap junctions between cells that have exited the cell cycle
and have reduced metabolism rates are important to: (i) maintain
adequate levels of GJIC, (ii) conserve energy by reducing the need
to constantly replenish gap junction plaques and (iii) promote
cell–cell adhesion, which may ultimately control processes such as
migration during wound healing. These unique features may
explain why mutations in the Cx30 gene (GJB6) are so detrimental
to normal physiology.
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MATERIALS AND METHODS
Generation of cDNA constructs
To create stable Cx26-, Cx30- and Cx43-expressing HeLa cells: the rat Cx26
pCR3 construct was a gift fromDrW. H. Evans and Dr P. Martin, University
of Wales College of Medicine, UK (Martin et al., 1999), and mouse Cx30
pCR3 construct was generated as described previously (Marziano et al.,
2003). All other experiments used the following DNA constructs: mouse
Cx30 encoded within the pBluescript vector was kindly provided by
Dr C. Naus (University of British Colombia, BC). To create a GFP-tagged
construct, Cx30 cDNA was subcloned into a pEGFP-N1 (Clontech)
expression vector, as described previously (Berger et al., 2014). Sar1 and
Sar1H79G cDNA were cloned into pDsRed2-N1 (Clontech) vectors as
described previously (Thomas et al., 2005).
Cell culture, transfections and generation of stable cell lines
All media and reagents were obtained from Invitrogen/Life Technologies
unless stated otherwise. Rat epidermal keratinocytes (REKs) were kindly
provided by Vincent C. Hascall (Cleveland Clinic, OH). HeLa and normal
rat kidney (NRK-52E) cells were obtained from the American Type Culture
Collection (ATCC). The HeLa cell line stably expressing mouse Cx43 was
kindly provided by Professor N. Severs (Imperial College London, UK) and
was maintained under hygromycin B (250 µg/ml) selection.
All cells were grown in high glucose Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, and 2 mM L-glutamine (‘DMEM complete’). For
transient transfections cells were grown to 70–80% confluency and
transfected with 1–3 µg DNA using Lipofectamine 2000, according to the
manufacturer’s guidelines. For co-transfections 1 µg DNA of each construct
(for a total of 2 µg) was used. Experiments were performed 24 h later. To
obtain stably transfected Cx26 and Cx30 HeLa cell lines, the cells were split
48 h after transfection into several 10 cm culture dishes containing DMEM
and 500 µg/ml of the selection antibiotic Geneticin (G418). After 7 days, the
concentration of G418 was reduced to 250 µg/ml to prevent cytotoxic
effects. Individual cell colonies with a diameter of 2–3 mm were harvested
using trypsin-soaked sterile cloning discs (3 mm, Sigma-Aldrich) and
transferred to a 24-well plate. Clonal cells were plated onto coverslips
between harvesting, fixed and checked for connexin expression using
immunofluorescent labelling, as described later.
NRK cells were engineered to stably express mouse Cx30 by retroviral
infection using the replication-defective AP2 vector (Galipeau et al., 1999)
as described previously (Mao et al., 2000; Qin et al., 2002; Thomas et al.,
2004). Briefly, the AP-2 vector containing Cx30 cDNAwas transfected into
the 293GPG packaging cell line. Supernatants containing retroviral particles
were collected, filter sterilized through a 0.45 μm filter (Pall Gelman
Laboratories) and added to the NRK cells. After three rounds of infection,
the cells were passaged and single cell colonies were selected. Clones with
100% Cx30 expression were selected for further experimentation.
Drug treatments
To block ER-to-Golgi transport, connexin-expressing cells were treated with
5 µg/ml brefeldin A (BFA; Sigma-Aldrich) for up to 18 h in DMEM
complete medium at 37°C. To examine the relative half-life of Cx30, REKs
were treated with 10 µg/ml of the translational inhibitor cycloheximide
(CHX; Sigma-Aldrich). To elucidate the role of cytoskeletal elements in the
stabilization of connexin plaques, Cx30- and Cx43-expressing REKs were
treated with the microtubule-disrupting drug nocodazole (10 μM; Sigma-
Aldrich) or with the actin depolymerization drug cytochalasin B (2.5 µg/ml;
Sigma-Aldrich) for up to 10 h in DMEM complete medium at 37°C.
Live cell time-lapse imaging and fluorescence recovery after
photobleaching
Cells expressing Cx30–GFP were plated into 35 mm glass-bottomed dishes
(MatTek). The dishes were mounted on a Zeiss 510 confocal microscope
fitted with a temperature (37°C) and CO2 (5%) control unit. Optical sections
at a single z-plane or in z-stack were acquired every 20–30 s for up to 2 h
using a 63× oil immersion lens (numerical aperture 1.4). Cx30-GFP was
excited using a 488 nm argon laser and emitted fluorescence was collected
after passage through a 500–550 nm band pass filter. In some cases,
fluorescent images were simultaneously acquired and superimposed over a
differential interference contrast (DIC) image. FRAP was performed on
specific Cx30–GFP gap junctions as described previously (Thomas et al.,
2005; Simek et al., 2009). Briefly, using ZEN 2011 (Zeiss) software a region
of interest (ROI) was drawn around the plaque to be bleached. After
acquiring 5–10 images at 20–30 s intervals, the ‘Edit Bleach’ function was
programmed to bleach the ROI using 30–60 iterations of the 488 laser at
100% emission intensity. Recovery of GFP fluorescence was then recorded
using the ‘Time Series’ function by continuously acquiring single z-plane or
z-stack images every 20–30 s for up to 2 h of total imaging time, using
the 488 nm laser line at 0.5% intensity. Three-dimensional time-lapse
recordings were reconstructed from the z-stack images using the ZEN 2011
3D software tool and exported as still images. The 3D time-lapse movies
were created using Imaris 7.0 (Bitplane).
Immunofluorescent labelling
Cells expressing Cx30 or Cx43 were fixed with 10% neutral buffered
formalin, permeabilized and blocked with 0.1% Triton X-100 (Sigma) and
3% bovine serum albumin (Santa Cruz Biotechnology) in phosphate-
buffered saline (PBS). The following primary antibodies were left on the
cells for 2 h at room temperature or at 4°C overnight: rabbit polyclonal
anti-Cx30 (0.63 µg/ml, Invitrogen, no. 71-2200), rabbit polyclonal anti-
Cx43 (1.4 µg/ml, Sigma-Aldrich, no. C6219), rabbit polyclonal anti-Cx26
(1.25 µg/ml, Invitrogen, no. 51-2800), mouse monoclonal anti-Cx43 (1:200
dilution, EMD Millipore, no. 05-763), mouse monoclonal anti-GM130
(0.63 µg/ml, BD Biosciences, no. 610822), mouse monoclonal anti-PDI
(3.3 µg/ml, Enzo Life Sciences, no. ADI-SPA-891), mouse monoclonal
anti-β-tubulin (2 µg/ml, Sigma-Aldrich, no. T8328). After washing in PBS,
cells were incubated for 1 h with the following secondary antibodies: goat
anti-mouse Alexa Fluor 488 or 555 (1:500 dilution, Invitrogen, no. A11017/
A21425) or goat anti-rabbit Alexa Fluor 488 or 555 (1:500 dilution,
Invitrogen, no. A11008/A21429). F-actin filaments were labelled with
phalloidin conjugated to Alexa Fluor 568 (1:500 dilution, Invitrogen, no.
A12380) or Alexa Fluor 488 (1:500 dilution, Invitrogen, no. A12379).
Nuclei were stained with Hoechst 33342 (10 µg/ml, Invitrogen, no. 62249)
or TO-PRO-3 (1:3000, Invitrogen, no. T3605) for 5 min. Cells were washed
with PBS, mounted on slides and imaged on a Zeiss 510 Meta confocal
microscope using a 63× oil immersion lens (1.4 numerical aperture).
Whole-cell tracer diffusion assay
To assess the extent of gap junctional coupling between stably expressing
Cx26, Cx30 or Cx43 HeLa cells after BFA treatment, a whole-cell
neurobiotin tracer study was performed as described previously (Kelly et al.,
2011). Briefly, HeLa cells grown on glass coverslips were pretreated with
BFA for 7 h or 0.01% (v/v) ethanol as a control. Coverslips were placed in
a recording chamber on an upright microscope (Axioskop; Zeiss) and
superfused with artificial extracellular solution (in mM: 145 NaCl, 4 KCl,
2 MgCl2, 1.3 CaCl2 and 5 glucose; pH adjusted to 7.3 with NaOH). Patch
pipettes were filled with a potassium chloride intracellular solution (in mM:
140 KCl, 10 NaCl, 2 MgCl2, 5 HEPES, 5 EGTA and 5 glucose; pH adjusted
to 7.3 with KOH) supplemented with 1 mg/ml neurobiotin (molecular mass
287 Da; charge +1, Vector Laboratories). Once a giga-seal was formed,
suction was applied to create the whole-cell configuration and to allow
neurobiotin to permeate the cell. After 10 min the pipette was gently
removed to form a tight seal. Cells were then fixed in 4% paraformaldehyde
for 30 min, permeabilized and blocked in 0.1% Triton X-100 and 0.1 mol/l
L-lysine for 30 min, before incubation for 2 h with Alexa Fluor 555-
conjugated streptavidin (1:1000; Invitrogen, no. S-32355). Images were
acquired on a Zeiss LSM 510 confocal microscope. All image settings were
kept constant between coverslips. ImageJ software was used to count cells
with neurobiotin present in the cytoplasm and nucleus. Data were collated,
presented as means±s.e.m. and statistically analysed using Student’s t-test in
GraphPad Prism4 software.
Western blotting
Cx30- and Cx43-expressing REK protein lysates were collected with a 1%
Triton X-100 lysis buffer, as described previously (Penuela et al., 2007).
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Protein concentrations were measured using a bicinchoninic acid (BCA)
protein determination kit (Pierce). In total, 20–30 μg of protein was resolved
using 10% SDS-PAGE and transferred to a nitrocellulose membrane
using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked
with 3% bovine serum albumin (BSA)–PBS containing 0.01% Tween
and probed with rabbit polyclonal anti-Cx30 (0.25 µg/ml, Invitrogen,
no. 71-2200), rabbit polyclonal anti-Cx43 (0.55 µg/ml, Sigma-Aldrich,
no. C6219) and mouse monoclonal GAPDH (0.1 µg/ml, Millipore, no.
MAB374). Primary antibodies were detected using the fluorescently
conjugated secondary antibodies goat anti-rabbit IRdye 800 (1:10,000
dilution, LI-COR Biosciences) and Alexa Fluor 680 goat anti-mouse
(1:10,000 dilution, Invitrogen, no. A21057). Membranes were scanned
and quantified using the Odyssey Infrared Imaging System (LI-COR
Biosciences). For CHX experiments, band intensities, normalized to the
0 h time point, were collated and a one-way ANOVA was performed
on the averages of three biological replicates. Densitometry units are
displayed ±s.e.m.
Triton solubility assay
Cx30- and Cx43-expressing REKs grown in 60 mm dishes were pretreated
with BFA for 7 h, washed with cold PBS and Triton solubility assessed as
described previously (Langlois et al., 2008), with modifications. Briefly,
cells were gently collected with a rubber policeman into 1 ml of cold PBS
and spun down to a pellet. Cells were gently resuspended in 300 µl Triton
lysis buffer containing 1% Triton X-100 plus 5 mM Tris-HCl (pH 8.0),
2 mM EDTA, 2 mM EGTA, 1 mM NaF, 1 mM Na3VO4 and protease
inhibitor (Roche). Cells were left for 30 min on ice before pelleting and
collecting the Triton-soluble supernatant. The remaining Triton-insoluble
material was then dissolved in lysis buffer containing 1% SDS with
sonication. Equal volumes of Triton X-100 soluble and insoluble fractions
were separated by SDS-PAGE and subjected to western blotting. GAPDH
was used to verify the quality of the isolated fractions. Densitometry data are
presented as means±s.e.m. and were statistically analysed using Student’s
t-test in GraphPad Prism4 software.
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Bosen, F., Schütz, M., Beinhauer, A., Strenzke, N., Franz, T. and Willecke, K.
(2014). The Clouston syndrome mutation connexin30 A88V leads to
hyperproliferation of sebaceous glands and hearing impairments in mice. FEBS
Lett. 588, 1795-1801.
Chang, Q., Tang, W., Ahmad, S., Zhou, B. and Lin, X. (2008). Gap junction
mediated intercellular metabolite transfer in the cochlea is compromised in
connexin30 null mice. PLoS ONE 3, e4088.
Chen, P., Zindy, F., Abdala, C., Liu, F., Li, X., Roussel, M. F. and Segil, N. (2003).
Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor
Ink4d. Nat. Cell Biol. 5, 422-426.
Churko, J. M. and Laird, D. W. (2013). Gap junction remodeling in skin repair
following wounding and disease. Physiology 28, 190-198.
Coutinho, P., Qiu, C., Frank, S., Tamber, K. and Becker, D. (2003). Dynamic
changes in connexin expression correlate with key events in the wound healing
process. Cell Biol. Int. 27, 525-541.
Dahl, E., Manthey, D., Chen, Y., Schwarz, H.-J., Chang, Y. S., Lalley, P. A.,
Nicholson, B. J. and Willecke, K. (1996). Molecular cloning and functional
expression of mouse connexin-30, a gap junction gene highly expressed in adult
brain and skin. J. Biol. Chem. 271, 17903-17910.
Darrow, B. J., Laing, J. G., Lampe, P. D., Saffitz, J. E. and Beyer, E. C. (1995).
Expression of multiple connexins in cultured neonatal rat ventricular myocytes.
Circ. Res. 76, 381-387.
Das, S., Smith, T. D., Sarma, J. D., Ritzenthaler, J. D., Maza, J., Kaplan, B. E.,
Cunningham, L. A., Suaud, L., Hubbard, M. J., Rubenstein, R. C. et al. (2009).
ERp29 restricts Connexin43 oligomerization in the endoplasmic reticulum. Mol.
Biol. Cell 20, 2593-2604.
Di, W.-L., Rugg, E. L., Leigh, I. M. and Kelsell, D. P. (2001). Multiple epidermal
connexins are expressed in different keratinocyte subpopulations including
connexin 31. J. Invest. Dermatol. 117, 958-964.
Elias, L. A. B., Wang, D. D. and Kriegstein, A. R. (2007). Gap junction adhesion is
necessary for radial migration in the neocortex. Nature 448, 901-907.
Essenfelder, G. M., Bruzzone, R., Lamartine, J., Charollais, A., Blanchet-
Bardon, C., Barbe, M. T., Meda, P. and Waksman, G. (2004). Connexin30
mutations responsible for hidrotic ectodermal dysplasia cause abnormal
hemichannel activity. Hum. Mol. Genet. 13, 1703-1714.
Evans, W. H., De Vuyst, E. and Leybaert, L. (2006). The gap junction cellular
internet: connexin hemichannels enter the signalling limelight. Biochem. J. 397,
1-14.
Falk, M. M. (2000). Connexin-specific distribution within gap junctions revealed in
living cells. J. Cell Sci. 113, 4109-4120.
Falk, M. M., Baker, S. M., Gumpert, A. M., Segretain, D. and Buckheit, R. W.III
(2009). Gap junction turnover is achieved by the internalization of small endocytic
double-membrane vesicles. Mol. Biol. Cell 20, 3342-3352.
Falk, M. M., Fong, J. T., Kells, R. M., O’Laughlin, M. C., Kowal, T. J. and
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